Biomaterial-assisted gene therapy for bone repair
Yang L., Li W., Yu Y., Wang H., Wang X.
Narrative Review, published in Mater Today Bio (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Mater Today Bio (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41716342
- PMCID
- PMC12914212
- DOI
- 10.1016/j.mtbio.2026.102886
- Citations
- 1
Abstract (original English)
Bone defects are a prevalent and serious condition that can give rise to pain, deformity, infection, and even serious consequences. However, conventional treatment modalities, whether conservative or surgical, are often limited by suboptimal outcomes, insufficient resources, or potential risks. Biomaterial-assisted gene therapy systems, an emerging interdisciplinary field integrating gene therapy and biomaterial technology, enhance gene therapy targeting, cellular uptake, and gene expression efficiency, facilitating a shift from natural bone grafts to artificial biomaterial substitutes. Below, we present a comprehensive review of current developments in biomaterial-assisted gene therapy for bone repair. Following a brief introduction of bone repair mechanisms and conventional treatment strategies, the foundations of biomaterial-assisted gene therapy for bone repair are elucidated from a holistic perspective, highlighting the three key elements: therapeutic genes, gene vectors, and biomaterials. Furthermore, current challenges and future research directions are discussed. The review is not confined to the summary of a single technology; rather, it aims to establish an overarching concept of biomaterial-assisted gene therapy and serve as a reference for future interdisciplinary studies.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.